10 Sarepta Therapeutics regulatory affairs leaders
Meghan Brown, Vice President - Head of Global Regulatory Affairs, is the most senior person among these Sarepta Therapeutics regulatory affairs leaders, who also hold current titles in global regulatory strategy, regulatory CMC and global regulatory operations. A reader can learn how regulatory affairs leaders work at Sarepta Therapeutics from people who have held the role.
Professionals to explore
Devyani Bhonsle
LinkedInExperience: Director CMC Regulatory Affairs - Gene Therapy · Sarepta Therapeutics
Devyani Bhonsle has been Director CMC Regulatory Affairs - Gene Therapy at Sarepta Therapeutics since May 2024, based in the New York City Metropolitan Area. Devyani Bhonsle was Senior Manager - Regulatory Affairs CMC, Cell & Gene Therapy at Novartis from 2019 to 2022 and Senior Specialist Regulatory Affairs CMC - Biologics at Merck from 2017 to 2019.
Ellen Wong
LinkedInExperience: Executive Director, Regulatory Labeling, Disclosures, and Promotional Review · Sarepta Therapeutics
Ellen Wong has been Executive Director, Regulatory Labeling, Disclosures, and Promotional Review at Sarepta Therapeutics since February 2022, based in Irvine, California. At Sarepta, Ellen Wong also held the Sr Director title in the same area from 2021 to 2022 and the Director title from 2018 to 2021, and was Director, Global Labeling at Allergan from 2016 to 2021.
Encarnacion Suarez
LinkedInExperience: Senior Director, Regulaty Affairs Strategy · Sarepta Therapeutics, Inc.
Encarnacion Suarez has been Senior Director, Regulaty Affairs Strategy at Sarepta Therapeutics, Inc. since May 2022, based in Florham Park, New Jersey, and the profile describes the role as global regulatory strategist for clinical and commercial therapeutic programs. Encarnacion Suarez was Senior Director, Regulatory Affairs Strategy at LEO Pharma from 2019 to 2022.
Franklin K. Akomeah
LinkedInExperience: Executive Director, Global Regulatory Strategy · Sarepta Therapeutics
Franklin K. Akomeah has been Executive Director, Global Regulatory Strategy at Sarepta Therapeutics since December 2024, based in the Dallas-Fort Worth Metroplex. Franklin K. Akomeah was Executive Director, Regulatory Affairs at Adverum Biotechnologies from 2022 to 2024 and Global Program Regulatory Director at Novartis from 2019 to 2021.
Jessica Romero
LinkedInExperience: Senior Director, Global Regulatory Operations · Sarepta Therapeutics
Jessica Romero has been Senior Director, Global Regulatory Operations at Sarepta Therapeutics since March 2026, based in San Francisco. At Sarepta, Jessica Romero was Director of Regulatory Operations from 2023 to 2026 and Associate Director of Regulatory Operations from 2022 to 2023, and was Associate Director of Regulatory Operations at Gilead Sciences from 2018 to 2022.
Meghan Brown
LinkedInExperience: Vice President - Head of Global Regulatory Affairs · Sarepta Therapeutics
Meghan Brown has been Vice President - Head of Global Regulatory Affairs at Sarepta Therapeutics since July 2025, based in Greater Boston, and also held Vice President - Global Regulatory Strategy there from 2024 to 2025. At Sarepta, Meghan Brown was Vice President - Global Regulatory Affairs CMC from 2023 to 2024 and Executive Director, Global Regulatory Affairs CMC from 2021 to 2023.
Ming Shen
LinkedInExperience: Executive Director, Global Regulatory Strategy · Sarepta Therapeutics
Ming Shen has been Executive Director, Global Regulatory Strategy at Sarepta Therapeutics since July 2025, based in Cambridge, Massachusetts, and also held Head of GRA Devices, CDx and Combination Products there from March to December 2025. At Sarepta, Ming Shen was Executive Director, Regulatory Affairs CMC from 2023 to 2025 and Senior Director, Regulatory Affairs CMC from 2021 to 2023.
Murat Karadeniz
LinkedInExperience: Director, Regulatory Affairs CMC · Sarepta Therapeutics
Murat Karadeniz has been Director, Regulatory Affairs CMC at Sarepta Therapeutics since March 2024, based in Cambridge, Massachusetts. Murat Karadeniz was Associate Director, Regulatory Affairs CMC at Sarepta from 2020 to 2024 and Senior Manager, Regulatory Affairs CMC at GSK from 2019 to 2020.
Patrick J. O'Malley
LinkedInExperience: Vice President, Global Regulatory Strategy · Sarepta Therapeutics
Patrick J. O'Malley has been Vice President, Global Regulatory Strategy at Sarepta Therapeutics since March 2023, based in Cambridge, Massachusetts. Patrick J. O'Malley was Executive Director, Regulatory Strategy at Sarepta from 2017 to 2023 and Senior Director, Global Regulatory Affairs at Eli Lilly and Company from 1989 to 2017.
Sema Ariman, RAC
LinkedInExperience: Executive Director, Global Regulatory Strategy · Sarepta Therapeutics
Sema Ariman has been Executive Director, Global Regulatory Strategy at Sarepta Therapeutics since September 2021, based in Greater Boston. Sema Ariman was Head of RNA Platform, Senior Director CMC Regulatory Affairs at Sarepta from 2019 to 2021 and Director, CMC Regulatory Affairs at Sage Therapeutics from 2016 to 2019.
Choose the right perspective
Start with the person whose title names the area your question touches, such as global strategy, CMC, labeling or operations. Then decide whether you need the view of someone who leads the whole function or of a director closer to daily regulatory work.
Questions to take into the conversation
- 01What did you focus on first when you took on your regulatory affairs role at Sarepta Therapeutics?
- 02How do you decide where to spend your own time across the regulatory work you lead?
- 03What has your own work at Sarepta Therapeutics taught you about building regulatory affairs capability?
Reaching Sarepta Therapeutics regulatory affairs leaders
How can I contact one of these Sarepta Therapeutics regulatory affairs leaders?
Pick one of the 10 people on this page and choose "Book a paid call", or describe your project to find others. You offer a fee for a 15-minute call or a written answer, Instant Expert finds the person's work email and sends the invitation, and they decide whether to accept. The list covers 2 companies: Sarepta Therapeutics and Sarepta Therapeutics, Inc., based on profile data retrieved on October 25, 2026. Being listed here doesn't mean someone has agreed to take calls.
How much does it cost to reach Sarepta Therapeutics regulatory affairs leaders?
You choose the offer, starting at $5 per person. The offer is what the person receives, and Instant Expert's fee is added on top, so a $100 offer costs you $125. The fee is 20% of what you pay. You're charged only when the person books the call or sends the answer.
What if they don't reply?
You pay nothing. Instant Expert sends follow-up reminders, and if the person hasn't booked or answered within 7 days, the request expires and any hold on your card is released. You can invite several of the 10 people on this list at once and cap your total spend, so you pay only for the ones who accept.
Can an AI agent ask one of these Sarepta Therapeutics regulatory affairs leaders a question?
Yes. An agent with a USDC wallet on Base can ask one question without an Instant Expert account. It names the person, for example by the LinkedIn URL on this page, and pays per ask over x402 (HTTP 402). The person answers in writing or by voice note, and if nobody answers within 7 days, the payment goes back to the wallet automatically. Claude and ChatGPT can do the same through the Instant Expert connector: setup is at /docs/mcp for Claude and /docs/chatgpt for ChatGPT. x402 docs
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.